Send to printer »

Insight & Intelligence™ : Jul 24, 2012

What the Top 10 Biopharma CEOs Are Making

GEN shows you who's in the money.
  • Alex Philippidis

#10. Merck & Co.

Kenneth C. Frazier, Chairman, President, and CEO

2011 Compensation: $13,347,652

2010 Compensation: $9,439,632

% Change: 41.1%

#9. Baxter International

Robert L. Parkinson Jr., Chairman and CEO

2011 Compensation: $14,065,479

2010 Compensation: $11,500,268

% Change: 22.3%

#8. Bristol-Myers Squibb

Lamberto Andreotti, CEO

2011 Compensation: $14,911,947

2010 Compensation: $11,770,880

% Change: 26.7%

#7. Gilead Sciences

John C. Martin, Chairman and CEO

2011 Compensation: $15,615,645

2010 Compensation: $14,244,388

% Change: 9.6%

#6. Novartis

Joseph Jimenez, CEO

2011 Compensation1: $15,881,621

2010 Compensation1: $11,828,828

% Change: 34.3%

#5. Eli Lilly

John C. Lechleiter, Ph.D., Chairman, President, and CEO

2011 Compensation: $16,370,094

2010 Compensation: $16,504,545

% Change: -0.8%

#4. Amgen

Kevin W. Sharer, Chairman and CEO

2011 Compensation: $18,850,311

2010 Compensation: $21,138,133

% Change: -10.8%

#3. Abbott

Miles D. White, Chairman, CEO, and Director

2011 Compensation: $24,010,902

2010 Compensation: $25,564,283

% Change: -6.1%

#2. Pfizer

Ian Read, Chairman and CEO

2011 Compensation: $25,013,348

2010 Compensation: $17,396,112

% Change: 43.8%

#1. Johnson & Johnson

William C. Weldon, Chairman/CEO

2011 Compensation: $26,797,939

2010 Compensation: $28,720,491

% Change: -6.7%

 

Leave a comment by clicking the “Comments” icon below. We want to hear your thoughts!